FDA approves Neurocrine Biosciences' Huntington's disease drug-February 2024-www.financetom.com

FDA approves Neurocrine Biosciences' Huntington's disease drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA approves Neurocrine Biosciences' Huntington's disease drug

Apr 30, 2024 3:02 PM

April 30 (Reuters) - The U.S. Food and Drug

Administration (FDA) has approved granule formulation of

Neurocrine Biosciences' ( NBIX ) drug to treat movement

disorders associated with Huntington's disease, the company said

on Tuesday.

Previous page： EXPLAINER-Prince Harry settles lawsuit against Rupert Murdoch's UK newspaper group Next page： Teledyne's fourth-quarter profit beats on robust defense demand

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

EXPLAINER-Prince Harry settles lawsuit against Rupert Murdoch's UK newspaper group

Jan 22, 2025

LONDON, Jan 22 (Reuters) - Prince Harry claimed victory in his long-running legal battle against Rupert Murdoch's British newspaper group, after reaching a deal to settle his lawsuit which included an apology for unlawful actions relating to the Sun for the first time. Here are details of the case: WHAT WAS THE CASE ABOUT? Harry was suing News Group Newspapers...

Teledyne's fourth-quarter profit beats on robust defense demand

Jan 22, 2025

Jan 22 (Reuters) - U.S. defense firm Teledyne ( TDY ) reported a fourth-quarter profit on Wednesday that beat analysts' estimates on the back of robust demand for its target detection sensors and marine equipment. On an adjusted basis, the company earned $5.52 per share in the quarter, compared with the average analyst estimate of $5.22, according to data compiled...

Textron forecasts 2025 profit below estimates; IAM strike dents Q4 jet deliveries

Jan 22, 2025

(Reuters) - Textron forecast 2025 profit below estimates on Wednesday, after missing quarterly revenue expectations due to the impact of the September strike on its aviation segment and demand softness in its industrial segment. Shares of the Providence, Rhode Island-based company were down nearly 4% before the bell. On an adjusted basis, the company forecast 2025 profit to range between...

Textron forecasts 2025 profit below estimates; IAM strike dents Q4 jet deliveries

Jan 22, 2025